Dectecting adverse drug reactions ================================= * David Rosenbloom * Christine Wynne In a CMAJ editorial, Namrata Bains and Duncan Hunter used hospital separation and mortality data to estimate that 0.05% of in-hospital mortality is associated with coded adverse drug reactions. [1] They extrapolated their data to rank mortality associated with adverse drug reactions as the 19th leading cause of death in Canada. This contrasts with the findings of Lazarou and colleagues, [2] who ranked adverse drug reactions as between the 4th and 6th leading cause of death in the US (106 000 deaths per year). The fundamental issue is whether coding adverse drug reactions in the medical record provides reliable and valid data on the true numbers of adverse drug reactions. Several studies have shown that self-reporting only identifies 5% of events. [3–5] Daily chart review and solicited reporting have detected 5 times as many adverse drug reactions as coding. [6] Methodologically, the first stage involved in linking a drug to an incident is the screening and correlation of an adverse clinical event to a specific drug. Thus, an adverse drug event only indicates suspected incidents, not causation. [6] Detection is better using a combination of complementary methods. [4, 7] Next, the probability of a drug causing the event is determined, and then the incident is classified as an adverse drug reaction, [8] using systematic criteria such as the algorithm of Naranjo and colleagues. [9] The annual number of deaths due to adverse drug reactions in Canada can be estimated using the 1:10 ratio of the population of Canada to that of the US. Bates and colleagues reported that 76 000 deaths are due to adverse drug reactions annually in the US. [6] This estimate would rank adverse drug reaction fatalities as the 7th leading cause of death in Canada, after cancer, heart disease, stroke, pulmonary disease and accidents, using 1995 Statistics Canada data. Adverse drug reactions prolong hospital stay by an average of 4.6 days in Canada, costing Can$300 million annually. [10] If one-third of adverse drug reaction deaths are preventable, [2, 6] then we should ensure that research dollars are used to minimize this problem. David Rosenbloom, PharmD Christine Wynne, BSc Phm McMaster University Medical Centre; Hamilton, Ont. ## References 1. 1. Bains N, Hunter D. Adverse reporting on adverse reactions. CMAJ1999;160(3):350-1. [FREE Full Text](http://www.cmaj.ca/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6MzoiUERGIjtzOjExOiJqb3VybmFsQ29kZSI7czo0OiJjbWFqIjtzOjU6InJlc2lkIjtzOjk6IjE2MC8zLzM1MCI7czo0OiJhdG9tIjtzOjIwOiIvY21hai8xNjEvMy8yNDcuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 2. 2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA1998;279:1200-5. [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1001/jama.279.15.1200&link_type=DOI) [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=9555760&link_type=MED&atom=%2Fcmaj%2F161%2F3%2F247.atom) [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=000072969400034&link_type=ISI) 3. 3. Keith, MR, Bellanger-McCleery RA, Fuchs JE. Multidisciplinary program for detecting and evaluating adverse drug reactions. Am J Hosp Pharm1989;46:1809-18. [Abstract](http://www.cmaj.ca/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NDoiYWpocCI7czo1OiJyZXNpZCI7czo5OiI0Ni85LzE4MDkiO3M6NDoiYXRvbSI7czoyMDoiL2NtYWovMTYxLzMvMjQ3LmF0b20iO31zOjg6ImZyYWdtZW50IjtzOjA6IiI7fQ==) 4. 4. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA1991;266:2847-51. [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1001/jama.1991.03470200059035&link_type=DOI) [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=1942452&link_type=MED&atom=%2Fcmaj%2F161%2F3%2F247.atom) [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=A1991GQ72200032&link_type=ISI) 5. 5. Cullen DJ, Bates DJ, Small SD, Coooper JB, Nemaskal AR, Leape LL. The incident reporting system does not detect adverse drug events: a problem for quality improvement. J Qual Improvement1995;21:541-8. 6. 6. Bates DW, Cullen DJ, Laird N, Peterson L, Small S, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. JAMA1995;274:29-34. [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1001/jama.1995.03530010043033&link_type=DOI) [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=7791255&link_type=MED&atom=%2Fcmaj%2F161%2F3%2F247.atom) [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=A1995RG23300027&link_type=ISI) 7. 7. Dalton-Bunnow MF, Halfachs FJ. Computer-assisted use of tracer antidote drugs to increase detection of adverse drug reactions: a retrospective and concurrent trial. Hosp Pharm1993;28:746-55. [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=10127575&link_type=MED&atom=%2Fcmaj%2F161%2F3%2F247.atom) 8. 8. Naranjo CA, Shear NH, Lanctot KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol1992;32:897-904. [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=1447396&link_type=MED&atom=%2Fcmaj%2F161%2F3%2F247.atom) [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=A1992JU00500004&link_type=ISI) 9. 9. Naranjo CA, Busto V, Seller EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981;30:239-45. [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1038/clpt.1981.154&link_type=DOI) [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=7249508&link_type=MED&atom=%2Fcmaj%2F161%2F3%2F247.atom) [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=A1981MC89700015&link_type=ISI) 10. 10. Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, et al. The costs of adverse drug events in hospitalized patients. JAMA1997;277:307-11. [CrossRef](http://www.cmaj.ca/lookup/external-ref?access_num=10.1001/jama.1997.03540280045032&link_type=DOI) [PubMed](http://www.cmaj.ca/lookup/external-ref?access_num=9002493&link_type=MED&atom=%2Fcmaj%2F161%2F3%2F247.atom) [Web of Science](http://www.cmaj.ca/lookup/external-ref?access_num=A1997WC45800030&link_type=ISI)